The Avanzar study could read out shortly.
ApexOnco Front Page
Recent articles
Satri-cel is filed for gastric cancer approval in China.
The group’s latest update focused on new data with the KRAS G12C inhibitor elironrasib.
Meanwhile, Exelixis and AstraZeneca continue to invest in pivotal trials of blockbuster follow-ons.
TAK-280 is among the group's discarded projects, although it’s a T-cell engager, not an ADC.
Dellphi-312, testing Imdelltra plus PD-(L)1, will start mid-year.
Conference activity picks up, with the big one – ASCO – at the end of the month.
Final survival analysis draws a blank, and Lantheus throws in the towel.
